Core Insights - Oncolytics Biotech Inc. is advancing its immunotherapeutic agent, pelareorep, towards registration-enabling studies for breast and pancreatic cancers, with positive feedback from the FDA regarding the study design for HR+/HER2- metastatic breast cancer [1][2][3] - The company has initiated the GOBLET study for pancreatic cancer, evaluating pelareorep in combination with modified FOLFIRINOX, supported by a $5 million grant from the Pancreatic Cancer Action Network (PanCAN) [1][4] - Oncolytics has a cash position of $24.9 million, providing a runway through key milestones into 2025 [1][7] Regulatory and Clinical Developments - The FDA has supported the use of progression-free survival as the primary endpoint and overall survival as a secondary endpoint for the pelareorep study in HR+/HER2- metastatic breast cancer [3] - The GOBLET study's fifth cohort will assess pelareorep combined with mFOLFIRINOX, with or without atezolizumab, in newly diagnosed pancreatic ductal adenocarcinoma patients [4][5] - A collaboration with the Global Coalition for Adaptive Research (GCAR) is underway to evaluate pelareorep in first-line metastatic pancreatic cancer, which has received Fast Track Designation from the FDA [5][6] Financial Performance - For Q2 2024, Oncolytics reported a net loss of $7.3 million, slightly improved from a net loss of $7.4 million in Q2 2023, with a basic and diluted loss per share of $0.10 [7][11] - Research and development expenses increased to $4.6 million in Q2 2024 from $3.7 million in Q2 2023, primarily due to higher clinical trial costs [7][11] - The company’s total assets as of June 30, 2024, were $32.1 million, down from $38.8 million at the end of 2023 [10] Upcoming Milestones - Overall survival results from the BRACELET-1 trial in HR+/HER2- metastatic breast cancer are expected in the second half of 2024 [9] - Finalization of the master protocol for the adaptive registration-enabling trial for pelareorep in first-line pancreatic cancer is anticipated in H2 2024 [9] - An update on the safety run-in for the GOBLET mFOLFIRINOX cohort is expected in H1 2025 [9]

SAN DIEGO, Calif. and CALGARY, Alberta, July 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the second quarter 2024. A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking h ...

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. The article continued: According to the World Health Organization, the global cancer burden is growing amidst a mounting need for services. As well, an alarming trend is emerging, where cancer cases in younger people are rising sharply. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that the Company received productive feedback from its T ...

Overall Survival data from BRACELET-1 breast cancer study continues to be expected in H2 2024 SAN DIEGO and CALGARY, AB, June 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that Matt Coffey, PhD, President and Chief Executive Officer of Oncolytics will take a medical leave of absence, effective immediately. Wayne Pisano, Chair of Oncolytics' Board of Directors, will serve as the in ...

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg and primary investigator of the GOBLET trial commented, "I have been pleased to observe the strength of the clinical response data for pelareorep in multiple cohorts of the GOBLET gastrointestinal study, especially in pancreatic and anal cancer. mFOLFIRINOX is currently considered the best treatment option for many pancreatic cancer patients. Therefore, the evaluati ...

Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit SAN DIEGO, and CALGARY, AB, June 20, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentri ...

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 19, 2024 /PRNewswire/ -- USA News Group – This year's 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for cancer patients around the world. This year's ASCO 2024 theme was 'The Art and Science of Cancer Care: From comfort to cure,' with attendees hearing presentations from experts and receiving a wide range of important clinical results for ...

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. Presented recently at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) presented two abstracts related to their novel immunotherapy, pelareorep, an intravenously delivered immunotherapeutic agent. "The first abstract outlines the design of a new GOBLET PDAC cohort that could significantly expand the potential of the company's pancreatic cancer program," said Dr. Matt C ...

A downtrend has been apparent in Oncolytics Biotech Inc. (ONCY) lately. While the stock has lost 9.3% over the past four weeks, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about ...

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 3, 2024 /PRNewswire/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins Medicine, up to 80% of patients are diagnosed at advanced stages, which are significantly harder to treat. A new study published in the journal Cell Genomics demonstrates that researchers have ...